TY - JOUR
T1 - Design, synthesis, and optimization of novel epoxide incorporating peptidomimetics as selective calpain inhibitors
AU - Schiefer, Isaac T.
AU - Tapadar, Subhasish
AU - Litosh, Vladislav
AU - Siklos, Marton
AU - Scism, Rob
AU - Wijewickrama, Gihani T.
AU - Chandrasena, Esala P.
AU - Sinha, Vaishali
AU - Tavassoli, Ehsan
AU - Brunsteiner, Michael
AU - Fa', Mauro
AU - Arancio, Ottavio
AU - Petukhov, Pavel
AU - Thatcher, Gregory R.J.
PY - 2013/8/8
Y1 - 2013/8/8
N2 - Hyperactivation of the calcium-dependent cysteine protease calpain 1 (Cal1) is implicated as a primary or secondary pathological event in a wide range of illnesses and in neurodegenerative states, including Alzheimer's disease (AD). E-64 is an epoxide-containing natural product identified as a potent nonselective, calpain inhibitor, with demonstrated efficacy in animal models of AD. By use of E-64 as a lead, three successive generations of calpain inhibitors were developed using computationally assisted design to increase selectivity for Cal1. First generation analogues were potent inhibitors, effecting covalent modification of recombinant Cal1 catalytic domain (Cal1cat), demonstrated using LC-MS/MS. Refinement yielded second generation inhibitors with improved selectivity. Further library expansion and ligand refinement gave three Cal1 inhibitors, one of which was designed as an activity-based protein profiling probe. These were determined to be irreversible and selective inhibitors by kinetics studies comparing full length Cal1 with the general cysteine protease papain.
AB - Hyperactivation of the calcium-dependent cysteine protease calpain 1 (Cal1) is implicated as a primary or secondary pathological event in a wide range of illnesses and in neurodegenerative states, including Alzheimer's disease (AD). E-64 is an epoxide-containing natural product identified as a potent nonselective, calpain inhibitor, with demonstrated efficacy in animal models of AD. By use of E-64 as a lead, three successive generations of calpain inhibitors were developed using computationally assisted design to increase selectivity for Cal1. First generation analogues were potent inhibitors, effecting covalent modification of recombinant Cal1 catalytic domain (Cal1cat), demonstrated using LC-MS/MS. Refinement yielded second generation inhibitors with improved selectivity. Further library expansion and ligand refinement gave three Cal1 inhibitors, one of which was designed as an activity-based protein profiling probe. These were determined to be irreversible and selective inhibitors by kinetics studies comparing full length Cal1 with the general cysteine protease papain.
UR - http://www.scopus.com/inward/record.url?scp=84881466563&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84881466563&partnerID=8YFLogxK
U2 - 10.1021/jm4006719
DO - 10.1021/jm4006719
M3 - Article
C2 - 23834438
AN - SCOPUS:84881466563
SN - 0022-2623
VL - 56
SP - 6054
EP - 6068
JO - Journal of Medicinal Chemistry
JF - Journal of Medicinal Chemistry
IS - 15
ER -